APO Research
Talk to an analyst

APO RESEARCH · REPORT

Brain and Central Nervous System Cancer Treatments

Compare research editions
View pricing & licenses

Selected research

Industry Research

Brain and Central Nervous System Cancer Treatments Industry Research Report 2026

28 December 2025148 pages

Choose your research edition.

Industry ResearchBrain and Central Nervous System Cancer Treatments Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Brain and Central Nervous System Cancer Treatments Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Brain and Central Nervous System Cancer Treatments Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Brain and Central Nervous System Cancer Treatments Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Brain and Central Nervous System Cancer Treatments Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Brain and Central Nervous System Cancer Treatments market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Brain and Central Nervous System Cancer Treatments is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Brain and Central Nervous System Cancer Treatments is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Brain and Central Nervous System Cancer Treatments is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Brain and Central Nervous System Cancer Treatments include Teva, Sanofi, Johnson & Johnson, Novartis, Merck & Co., Roche, Pfizer, Bayer and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Brain and Central Nervous System Cancer Treatments market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Brain and Central Nervous System Cancer Treatments Market by Company

Teva

Sanofi

Johnson & Johnson

Novartis

Merck & Co.

Roche

Pfizer

Bayer

AbbVie

Takeda

Otsuka

Merck KGaA

Ipsen

Gilead Sciences

Eli Lilly

Eisai

Celgene

Bristol-Myers Squibb

Biogen Idec

AstraZeneca

Astellas

Amgen

Brain and Central Nervous System Cancer Treatments Segment by Type

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Chemotherapy

Targeted Therapy

Others

Brain and Central Nervous System Cancer Treatments Segment by Application

Brain Cancer

Spinal Cord Cancer

Others

Brain and Central Nervous System Cancer Treatments Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Brain and Central Nervous System Cancer Treatments market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Brain and Central Nervous System Cancer Treatments and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Brain and Central Nervous System Cancer Treatments.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Brain and Central Nervous System Cancer Treatments manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Brain and Central Nervous System Cancer Treatments by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Brain and Central Nervous System Cancer Treatments in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Brain and Central Nervous System Cancer Treatments Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Brain and Central Nervous System Cancer Treatments Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Manufacturers (2021-2026) Table 8. Global Brain and Central Nervous System Cancer Treatments Revenue of Manufacturers (2021-2026) Table 9. Global Brain and Central Nervous System Cancer Treatments Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Brain and Central Nervous System Cancer Treatments Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Brain and Central Nervous System Cancer Treatments Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Brain and Central Nervous System Cancer Treatments, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Brain and Central Nervous System Cancer Treatments, Product Type & Application Table 14. Global Brain and Central Nervous System Cancer Treatments Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Brain and Central Nervous System Cancer Treatments by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Company Information Table 19. Teva Business Overview Table 20. Teva Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Teva Brain and Central Nervous System Cancer Treatments Product Portfolio Table 22. Teva Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sanofi Brain and Central Nervous System Cancer Treatments Product Portfolio Table 27. Sanofi Recent Developments Table 28. Johnson & Johnson Company Information Table 29. Johnson & Johnson Business Overview Table 30. Johnson & Johnson Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Johnson & Johnson Brain and Central Nervous System Cancer Treatments Product Portfolio Table 32. Johnson & Johnson Recent Developments Table 33. Novartis Company Information Table 34. Novartis Business Overview Table 35. Novartis Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Novartis Brain and Central Nervous System Cancer Treatments Product Portfolio Table 37. Novartis Recent Developments Table 38. Merck & Co. Company Information Table 39. Merck & Co. Business Overview Table 40. Merck & Co. Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Merck & Co. Brain and Central Nervous System Cancer Treatments Product Portfolio Table 42. Merck & Co. Recent Developments Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Roche Brain and Central Nervous System Cancer Treatments Product Portfolio Table 47. Roche Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Pfizer Brain and Central Nervous System Cancer Treatments Product Portfolio Table 52. Pfizer Recent Developments Table 53. Bayer Company Information Table 54. Bayer Business Overview Table 55. Bayer Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Bayer Brain and Central Nervous System Cancer Treatments Product Portfolio Table 57. Bayer Recent Developments Table 58. AbbVie Company Information Table 59. AbbVie Business Overview Table 60. AbbVie Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. AbbVie Brain and Central Nervous System Cancer Treatments Product Portfolio Table 62. AbbVie Recent Developments Table 63. Takeda Company Information Table 64. Takeda Business Overview Table 65. Takeda Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Takeda Brain and Central Nervous System Cancer Treatments Product Portfolio Table 67. Takeda Recent Developments Table 68. Otsuka Company Information Table 69. Otsuka Business Overview Table 70. Otsuka Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Otsuka Brain and Central Nervous System Cancer Treatments Product Portfolio Table 72. Otsuka Recent Developments Table 73. Merck KGaA Company Information Table 74. Merck KGaA Business Overview Table 75. Merck KGaA Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Merck KGaA Brain and Central Nervous System Cancer Treatments Product Portfolio Table 77. Merck KGaA Recent Developments Table 78. Ipsen Company Information Table 79. Ipsen Business Overview Table 80. Ipsen Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Ipsen Brain and Central Nervous System Cancer Treatments Product Portfolio Table 82. Ipsen Recent Developments Table 83. Gilead Sciences Company Information Table 84. Gilead Sciences Business Overview Table 85. Gilead Sciences Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Gilead Sciences Brain and Central Nervous System Cancer Treatments Product Portfolio Table 87. Gilead Sciences Recent Developments Table 88. Eli Lilly Company Information Table 89. Eli Lilly Business Overview Table 90. Eli Lilly Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Eli Lilly Brain and Central Nervous System Cancer Treatments Product Portfolio Table 92. Eli Lilly Recent Developments Table 93. Eisai Company Information Table 94. Eisai Business Overview Table 95. Eisai Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Eisai Brain and Central Nervous System Cancer Treatments Product Portfolio Table 97. Eisai Recent Developments Table 98. Celgene Company Information Table 99. Celgene Business Overview Table 100. Celgene Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Celgene Brain and Central Nervous System Cancer Treatments Product Portfolio Table 102. Celgene Recent Developments Table 103. Bristol-Myers Squibb Company Information Table 104. Bristol-Myers Squibb Business Overview Table 105. Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Product Portfolio Table 107. Bristol-Myers Squibb Recent Developments Table 108. Biogen Idec Company Information Table 109. Biogen Idec Business Overview Table 110. Biogen Idec Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Biogen Idec Brain and Central Nervous System Cancer Treatments Product Portfolio Table 112. Biogen Idec Recent Developments Table 113. AstraZeneca Company Information Table 114. AstraZeneca Business Overview Table 115. AstraZeneca Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. AstraZeneca Brain and Central Nervous System Cancer Treatments Product Portfolio Table 117. AstraZeneca Recent Developments Table 118. Astellas Company Information Table 119. Astellas Business Overview Table 120. Astellas Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Astellas Brain and Central Nervous System Cancer Treatments Product Portfolio Table 122. Astellas Recent Developments Table 123. Amgen Company Information Table 124. Amgen Business Overview Table 125. Amgen Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Amgen Brain and Central Nervous System Cancer Treatments Product Portfolio Table 127. Amgen Recent Developments Table 128. Global Brain and Central Nervous System Cancer Treatments Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 129. Global Brain and Central Nervous System Cancer Treatments Sales by Region (2021-2026) & (K Units) Table 130. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Region (2021-2026) Table 131. Global Brain and Central Nervous System Cancer Treatments Sales by Region (2027-2032) & (K Units) Table 132. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Region (2027-2032) Table 133. Global Brain and Central Nervous System Cancer Treatments Revenue by Region (2021-2026) & (US$ Million) Table 134. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Region (2021-2026) Table 135. Global Brain and Central Nervous System Cancer Treatments Revenue by Region (2027-2032) & (US$ Million) Table 136. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Region (2027-2032) Table 137. North America Brain and Central Nervous System Cancer Treatments Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. North America Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026) & (K Units) Table 139. North America Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032) & (K Units) Table 140. North America Brain and Central Nervous System Cancer Treatments Revenue by Country (2021-2026) & (US$ Million) Table 141. North America Brain and Central Nervous System Cancer Treatments Revenue by Country (2027-2032) & (US$ Million) Table 142. Europe Brain and Central Nervous System Cancer Treatments Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Europe Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026) & (K Units) Table 144. Europe Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032) & (K Units) Table 145. Europe Brain and Central Nervous System Cancer Treatments Revenue by Country (2021-2026) & (US$ Million) Table 146. Europe Brain and Central Nervous System Cancer Treatments Revenue by Country (2027-2032) & (US$ Million) Table 147. Asia Pacific Brain and Central Nervous System Cancer Treatments Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026) & (K Units) Table 149. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032) & (K Units) Table 150. Asia Pacific Brain and Central Nervous System Cancer Treatments Revenue by Country (2021-2026) & (US$ Million) Table 151. Asia Pacific Brain and Central Nervous System Cancer Treatments Revenue by Country (2027-2032) & (US$ Million) Table 152. South America Brain and Central Nervous System Cancer Treatments Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. South America Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026) & (K Units) Table 154. South America Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032) & (K Units) Table 155. South America Brain and Central Nervous System Cancer Treatments Revenue by Country (2021-2026) & (US$ Million) Table 156. South America Brain and Central Nervous System Cancer Treatments Revenue by Country (2027-2032) & (US$ Million) Table 157. Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2026) & (K Units) Table 159. Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales by Country (2027-2032) & (K Units) Table 160. Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue by Country (2021-2026) & (US$ Million) Table 161. Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue by Country (2027-2032) & (US$ Million) Table 162. Global Brain and Central Nervous System Cancer Treatments Sales by Type (2021-2026) & (K Units) Table 163. Global Brain and Central Nervous System Cancer Treatments Sales by Type (2027-2032) & (K Units) Table 164. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2021-2026) Table 165. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2027-2032) Table 166. Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2021-2026) & (US$ Million) Table 167. Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2027-2032) & (US$ Million) Table 168. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2021-2026) Table 169. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2027-2032) Table 170. Global Brain and Central Nervous System Cancer Treatments Price by Type (2021-2026) & (US$/Unit) Table 171. Global Brain and Central Nervous System Cancer Treatments Price by Type (2027-2032) & (US$/Unit) Table 172. Global Brain and Central Nervous System Cancer Treatments Sales by Application (2021-2026) & (K Units) Table 173. Global Brain and Central Nervous System Cancer Treatments Sales by Application (2027-2032) & (K Units) Table 174. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2021-2026) Table 175. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2027-2032) Table 176. Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2021-2026) & (US$ Million) Table 177. Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2027-2032) & (US$ Million) Table 178. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2021-2026) Table 179. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2027-2032) Table 180. Global Brain and Central Nervous System Cancer Treatments Price by Application (2021-2026) & (US$/Unit) Table 181. Global Brain and Central Nervous System Cancer Treatments Price by Application (2027-2032) & (US$/Unit) Table 182. Key Raw Materials Table 183. Raw Materials Key Suppliers Table 184. Brain and Central Nervous System Cancer Treatments Distributors List Table 185. Brain and Central Nervous System Cancer Treatments Customers List Table 186. Brain and Central Nervous System Cancer Treatments Industry Trends Table 187. Brain and Central Nervous System Cancer Treatments Industry Drivers Table 188. Brain and Central Nervous System Cancer Treatments Industry Restraints Table 189. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Brain and Central Nervous System Cancer Treatments Product Image Figure 5. Global Brain and Central Nervous System Cancer Treatments Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Brain and Central Nervous System Cancer Treatments Market Size (2021-2032) & (US$ Million) Figure 7. Global Brain and Central Nervous System Cancer Treatments Sales (2021-2032) & (K Units) Figure 8. Global Brain and Central Nervous System Cancer Treatments Average Price (US$/Unit) & (2021-2032) Figure 9. Immunotherapy (Biologic Therapy) Product Image Figure 10. Hormonal Therapy Product Image Figure 11. Chemotherapy Product Image Figure 12. Targeted Therapy Product Image Figure 13. Others Product Image Figure 14. Brain Cancer Product Image Figure 15. Spinal Cord Cancer Product Image Figure 16. Others Product Image Figure 17. Global Brain and Central Nervous System Cancer Treatments Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Brain and Central Nervous System Cancer Treatments, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Brain and Central Nervous System Cancer Treatments Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Brain and Central Nervous System Cancer Treatments Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Brain and Central Nervous System Cancer Treatments Sales by Region in 2025 Figure 23. Global Brain and Central Nervous System Cancer Treatments Revenue by Region in 2025 Figure 24. North America Brain and Central Nervous System Cancer Treatments Market Size by Country in 2025 Figure 25. North America Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021-2032) Figure 26. North America Brain and Central Nervous System Cancer Treatments Revenue Market Share by Country (2021-2032) Figure 27. United States Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Brain and Central Nervous System Cancer Treatments Market Size by Country in 2025 Figure 31. Europe Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021-2032) Figure 32. Europe Brain and Central Nervous System Cancer Treatments Revenue Market Share by Country (2021-2032) Figure 33. Germany Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Brain and Central Nervous System Cancer Treatments Market Size by Country in 2025 Figure 44. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Brain and Central Nervous System Cancer Treatments Revenue Market Share by Country (2021-2032) Figure 46. China Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Brain and Central Nervous System Cancer Treatments Market Size by Country in 2025 Figure 55. South America Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021-2032) Figure 56. South America Brain and Central Nervous System Cancer Treatments Revenue Market Share by Country (2021-2032) Figure 57. Brazil Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Colombia Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Brain and Central Nervous System Cancer Treatments Market Size by Country in 2025 Figure 62. Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue Market Share by Country (2021-2032) Figure 64. Egypt Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2021-2032) Figure 70. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2021-2032) Figure 71. Global Brain and Central Nervous System Cancer Treatments Price (US$/Unit) by Type (2021-2032) Figure 72. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2021-2032) Figure 73. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2021-2032) Figure 74. Global Brain and Central Nervous System Cancer Treatments Price (US$/Unit) by Application (2021-2032) Figure 75. Brain and Central Nervous System Cancer Treatments Value Chain Figure 76. Brain and Central Nervous System Cancer Treatments Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Brain and Central Nervous System Cancer Treatments Industry Opportunities and Challenges

Scope & coverage.

Types
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Chemotherapy
  • Targeted Therapy
  • Others
Applications
  • Brain Cancer
  • Spinal Cord Cancer
  • Others
Companies covered
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co.
  • Roche
  • Pfizer
  • Bayer
  • AbbVie
  • Takeda
  • Otsuka
  • Merck KGaA
  • Ipsen
  • Gilead Sciences
  • Eli Lilly
  • Eisai
  • Celgene
  • Bristol-Myers Squibb
  • Biogen Idec
  • AstraZeneca
  • Astellas
  • Amgen

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Brain and Central Nervous System Cancer Treatments Market Size (2021-2032)
  4. 2.2.2 Global Brain and Central Nervous System Cancer Treatments Sales (2021-2032)
  5. 2.2.3 Global Brain and Central Nervous System Cancer Treatments Market Average Price (2021-2032)
  6. 2.3 Brain and Central Nervous System Cancer Treatments by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Immunotherapy (Biologic Therapy)
  9. 2.3.3 Hormonal Therapy
  10. 2.3.4 Chemotherapy
  11. 2.3.5 Targeted Therapy
  12. 2.3.6 Others
  13. 2.4 Brain and Central Nervous System Cancer Treatments by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Brain Cancer
  16. 2.4.3 Spinal Cord Cancer
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Brain and Central Nervous System Cancer Treatments Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Brain and Central Nervous System Cancer Treatments Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Brain and Central Nervous System Cancer Treatments Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Brain and Central Nervous System Cancer Treatments Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Brain and Central Nervous System Cancer Treatments Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Brain and Central Nervous System Cancer Treatments, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Brain and Central Nervous System Cancer Treatments, Product Type & Application
  8. 3.8 Global Manufacturers of Brain and Central Nervous System Cancer Treatments, Established Date
  9. 3.9 Global Brain and Central Nervous System Cancer Treatments Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva
  2. 4.1.1 Teva Company Information
  3. 4.1.2 Teva Business Overview
  4. 4.1.3 Teva Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Brain and Central Nervous System Cancer Treatments Product Portfolio
  6. 4.1.5 Teva Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Brain and Central Nervous System Cancer Treatments Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Johnson & Johnson
  14. 4.3.1 Johnson & Johnson Company Information
  15. 4.3.2 Johnson & Johnson Business Overview
  16. 4.3.3 Johnson & Johnson Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Johnson & Johnson Brain and Central Nervous System Cancer Treatments Product Portfolio
  18. 4.3.5 Johnson & Johnson Recent Developments
  19. 4.4 Novartis
  20. 4.4.1 Novartis Company Information
  21. 4.4.2 Novartis Business Overview
  22. 4.4.3 Novartis Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis Brain and Central Nervous System Cancer Treatments Product Portfolio
  24. 4.4.5 Novartis Recent Developments
  25. 4.5 Merck & Co.
  26. 4.5.1 Merck & Co. Company Information
  27. 4.5.2 Merck & Co. Business Overview
  28. 4.5.3 Merck & Co. Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Merck & Co. Brain and Central Nervous System Cancer Treatments Product Portfolio
  30. 4.5.5 Merck & Co. Recent Developments
  31. 4.6 Roche
  32. 4.6.1 Roche Company Information
  33. 4.6.2 Roche Business Overview
  34. 4.6.3 Roche Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Roche Brain and Central Nervous System Cancer Treatments Product Portfolio
  36. 4.6.5 Roche Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Brain and Central Nervous System Cancer Treatments Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 Bayer
  44. 4.8.1 Bayer Company Information
  45. 4.8.2 Bayer Business Overview
  46. 4.8.3 Bayer Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Bayer Brain and Central Nervous System Cancer Treatments Product Portfolio
  48. 4.8.5 Bayer Recent Developments
  49. 4.9 AbbVie
  50. 4.9.1 AbbVie Company Information
  51. 4.9.2 AbbVie Business Overview
  52. 4.9.3 AbbVie Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AbbVie Brain and Central Nervous System Cancer Treatments Product Portfolio
  54. 4.9.5 AbbVie Recent Developments
  55. 4.10 Takeda
  56. 4.10.1 Takeda Company Information
  57. 4.10.2 Takeda Business Overview
  58. 4.10.3 Takeda Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Takeda Brain and Central Nervous System Cancer Treatments Product Portfolio
  60. 4.10.5 Takeda Recent Developments
  61. 4.11 Otsuka
  62. 4.11.1 Otsuka Company Information
  63. 4.11.2 Otsuka Business Overview
  64. 4.11.3 Otsuka Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Otsuka Brain and Central Nervous System Cancer Treatments Product Portfolio
  66. 4.11.5 Otsuka Recent Developments
  67. 4.12 Merck KGaA
  68. 4.12.1 Merck KGaA Company Information
  69. 4.12.2 Merck KGaA Business Overview
  70. 4.12.3 Merck KGaA Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Merck KGaA Brain and Central Nervous System Cancer Treatments Product Portfolio
  72. 4.12.5 Merck KGaA Recent Developments
  73. 4.13 Ipsen
  74. 4.13.1 Ipsen Company Information
  75. 4.13.2 Ipsen Business Overview
  76. 4.13.3 Ipsen Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Ipsen Brain and Central Nervous System Cancer Treatments Product Portfolio
  78. 4.13.5 Ipsen Recent Developments
  79. 4.14 Gilead Sciences
  80. 4.14.1 Gilead Sciences Company Information
  81. 4.14.2 Gilead Sciences Business Overview
  82. 4.14.3 Gilead Sciences Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Gilead Sciences Brain and Central Nervous System Cancer Treatments Product Portfolio
  84. 4.14.5 Gilead Sciences Recent Developments
  85. 4.15 Eli Lilly
  86. 4.15.1 Eli Lilly Company Information
  87. 4.15.2 Eli Lilly Business Overview
  88. 4.15.3 Eli Lilly Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Eli Lilly Brain and Central Nervous System Cancer Treatments Product Portfolio
  90. 4.15.5 Eli Lilly Recent Developments
  91. 4.16 Eisai
  92. 4.16.1 Eisai Company Information
  93. 4.16.2 Eisai Business Overview
  94. 4.16.3 Eisai Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Eisai Brain and Central Nervous System Cancer Treatments Product Portfolio
  96. 4.16.5 Eisai Recent Developments
  97. 4.17 Celgene
  98. 4.17.1 Celgene Company Information
  99. 4.17.2 Celgene Business Overview
  100. 4.17.3 Celgene Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Celgene Brain and Central Nervous System Cancer Treatments Product Portfolio
  102. 4.17.5 Celgene Recent Developments
  103. 4.18 Bristol-Myers Squibb
  104. 4.18.1 Bristol-Myers Squibb Company Information
  105. 4.18.2 Bristol-Myers Squibb Business Overview
  106. 4.18.3 Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Product Portfolio
  108. 4.18.5 Bristol-Myers Squibb Recent Developments
  109. 4.19 Biogen Idec
  110. 4.19.1 Biogen Idec Company Information
  111. 4.19.2 Biogen Idec Business Overview
  112. 4.19.3 Biogen Idec Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Biogen Idec Brain and Central Nervous System Cancer Treatments Product Portfolio
  114. 4.19.5 Biogen Idec Recent Developments
  115. 4.20 AstraZeneca
  116. 4.20.1 AstraZeneca Company Information
  117. 4.20.2 AstraZeneca Business Overview
  118. 4.20.3 AstraZeneca Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 AstraZeneca Brain and Central Nervous System Cancer Treatments Product Portfolio
  120. 4.20.5 AstraZeneca Recent Developments
  121. 4.21 Astellas
  122. 4.21.1 Astellas Company Information
  123. 4.21.2 Astellas Business Overview
  124. 4.21.3 Astellas Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Astellas Brain and Central Nervous System Cancer Treatments Product Portfolio
  126. 4.21.5 Astellas Recent Developments
  127. 4.22 Amgen
  128. 4.22.1 Amgen Company Information
  129. 4.22.2 Amgen Business Overview
  130. 4.22.3 Amgen Brain and Central Nervous System Cancer Treatments Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Amgen Brain and Central Nervous System Cancer Treatments Product Portfolio
  132. 4.22.5 Amgen Recent Developments
5 Global Brain and Central Nervous System Cancer Treatments Market Scenario by Region
  1. 5.1 Global Brain and Central Nervous System Cancer Treatments Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2021-2032
  3. 5.2.1 Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2021-2026
  4. 5.2.2 Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2027-2032
  5. 5.3 Global Brain and Central Nervous System Cancer Treatments Revenue by Region: 2021-2032
  6. 5.3.1 Global Brain and Central Nervous System Cancer Treatments Revenue by Region: 2021-2026
  7. 5.3.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Region: 2027-2032
  8. 5.4 North America Brain and Central Nervous System Cancer Treatments Market Facts & Figures by Country
  9. 5.4.1 North America Brain and Central Nervous System Cancer Treatments Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2032)
  11. 5.4.3 North America Brain and Central Nervous System Cancer Treatments Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Brain and Central Nervous System Cancer Treatments Market Facts & Figures by Country
  16. 5.5.1 Europe Brain and Central Nervous System Cancer Treatments Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2032)
  18. 5.5.3 Europe Brain and Central Nervous System Cancer Treatments Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Brain and Central Nervous System Cancer Treatments Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Brain and Central Nervous System Cancer Treatments Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Brain and Central Nervous System Cancer Treatments Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Brain and Central Nervous System Cancer Treatments Market Facts & Figures by Country
  41. 5.7.1 South America Brain and Central Nervous System Cancer Treatments Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2032)
  43. 5.7.3 South America Brain and Central Nervous System Cancer Treatments Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Brain and Central Nervous System Cancer Treatments Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Brain and Central Nervous System Cancer Treatments Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Brain and Central Nervous System Cancer Treatments Sales by Type (2021-2032)
  2. 6.1.1 Global Brain and Central Nervous System Cancer Treatments Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2021-2032)
  4. 6.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2021-2032)
  5. 6.2.1 Global Brain and Central Nervous System Cancer Treatments Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Brain and Central Nervous System Cancer Treatments Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Brain and Central Nervous System Cancer Treatments Sales by Application (2021-2032)
  2. 7.1.1 Global Brain and Central Nervous System Cancer Treatments Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2021-2032)
  4. 7.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2021-2032)
  5. 7.2.1 Global Brain and Central Nervous System Cancer Treatments Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Brain and Central Nervous System Cancer Treatments Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Brain and Central Nervous System Cancer Treatments Value Chain Analysis
  2. 8.1.1 Brain and Central Nervous System Cancer Treatments Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Brain and Central Nervous System Cancer Treatments Production Mode & Process
  5. 8.2 Brain and Central Nervous System Cancer Treatments Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Brain and Central Nervous System Cancer Treatments Distributors
  8. 8.2.3 Brain and Central Nervous System Cancer Treatments Customers
9 Global Brain and Central Nervous System Cancer Treatments Analyzing Market Dynamics
  1. 9.1 Brain and Central Nervous System Cancer Treatments Industry Trends
  2. 9.2 Brain and Central Nervous System Cancer Treatments Industry Drivers
  3. 9.3 Brain and Central Nervous System Cancer Treatments Industry Opportunities and Challenges
  4. 9.4 Brain and Central Nervous System Cancer Treatments Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst